Catherine M. Szyman net worth and biography

Catherine Szyman Biography and Net Worth

Catherine "Katie" Szyman is the corporate vice president, critical care at Edwards Lifesciences Corp., a role she has held since 2015.

Prior to Edwards, Szyman spent over 20 years at Medtronic, where she held the role of SVP and president of its global diabetes business from 2009 to 2014, overseeing research, development, sales, marketing and operations for its insulin infusion pumps and continuous glucose monitoring systems.

Additionally, Szyman held multiple leadership positions at Medtronic, including SVP of corporate strategy and business development, general manager of endovascular innovations and VP of finance for the cardiovascular business. She currently sits on the boards of Endotronix, Octane OC, Outset Medical, the American Heart Association of Orange County, Opus School of Business and Inari Medical, and she previously served on the boards of Inspire Medical Systems, Tornier, and the California Healthcare Institute.

Szyman earned her bachelor’s degree from the University of St. Thomas in St. Paul, Minnesota, and she holds an M.B.A. from Harvard Business School.

What is Catherine M. Szyman's net worth?: The estimated net worth of Catherine M. Szyman is at least $2.47 million as of February 15th, 2024. Ms. Szyman owns 34,814 shares of Edwards Lifesciences stock worth more than $2,468,173 as of March 29th. This net worth approximation does not reflect any other assets that Ms. Szyman may own. Learn More about Catherine M. Szyman's net worth.
How do I contact Catherine M. Szyman?: The corporate mailing address for Ms. Szyman and other Edwards Lifesciences executives is ONE EDWARDS WAY, IRVINE CA, 92614. Edwards Lifesciences can also be reached via phone at (949) 250-2500 and via email at investor_relations@edwards.com. Learn More on Catherine M. Szyman's contact information.
Has Catherine M. Szyman been buying or selling shares of Edwards Lifesciences?: Catherine M. Szyman has not been actively trading shares of Edwards Lifesciences within the last three months. Most recently, Catherine M. Szyman sold 27,000 shares of the business's stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $85.62, for a transaction totalling $2,311,740.00. Following the completion of the sale, the vice president now directly owns 34,814 shares of the company's stock, valued at $2,980,774.68. Learn More on Catherine M. Szyman's trading history.
Who are Edwards Lifesciences' active insiders?: Edwards Lifesciences' insider roster includes Donald Bobo, Jr (VP), Daveen Chopra (VP), Kieran Gallahue (Director), Leslie Heisz (Director), Jean-Luc Lemercier (VP), Daniel Lippis (VP), Martha Marsh (Director), Michael Mussallem (CEO), Robert Sellers (VP), Catherine Szyman (VP), Scott Ullem (CFO), Nicholas Valeriani (Director), Huimin Wang (VP), Larry Wood (VP), and Bernard Zovighian (VP). Learn More on Edwards Lifesciences' active insiders.
Are insiders buying or selling shares of Edwards Lifesciences?: In the last year, Edwards Lifesciences insiders bought shares 1 times. They purchased a total of 580 shares worth more than $49,729.20. In the last year, insiders at the medical research company sold shares 28 times. They sold a total of 243,407 shares worth more than $19,507,015.48. The most recent insider tranaction occured on March, 26th when CFO Scott B Ullem sold 11,250 shares worth more than $797,287.50. Insiders at Edwards Lifesciences own 1.3% of the company. Learn More about insider trades at Edwards Lifesciences.
Information on this page was last updated on 3/26/2025.

Catherine M. Szyman Insider Trading History at Edwards Lifesciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/15/2024	Sell	27,000	$85.62	$2,311,740.00	34,814
10/10/2023	Sell	5,000	$72.68	$363,400.00	34,814
9/8/2023	Sell	5,000	$76.00	$380,000.00	34,814
8/9/2023	Sell	5,000	$78.64	$393,200.00	34,814
7/10/2023	Sell	5,000	$90.52	$452,600.00	34,814
6/13/2023	Sell	5,000	$85.81	$429,050.00	35,056
5/4/2022	Sell	23,400	$104.86	$2,453,724.00	30,851
4/11/2022	Sell	20,000	$122.04	$2,440,800.00	27,569
3/14/2022	Sell	20,000	$104.65	$2,093,000.00
2/18/2022	Sell	20,000	$106.31	$2,126,200.00
1/14/2022	Sell	10,000	$119.53	$1,195,300.00
12/17/2021	Sell	10,000	$121.24	$1,212,400.00
11/18/2021	Sell	10,000	$117.79	$1,177,900.00
10/18/2021	Sell	9,741	$110.41	$1,075,503.81
8/2/2021	Sell	15,000	$113.53	$1,702,950.00	42,759
5/28/2021	Sell	2,061	$95.29	$196,392.69	27,705
5/25/2021	Sell	4,665	$96.09	$448,259.85	29,766
4/22/2021	Sell	3,389	$94.40	$319,921.60	30,355
3/15/2021	Sell	3,389	$81.66	$276,745.74
2/16/2021	Sell	3,389	$88.20	$298,909.80	30,135
10/29/2020	Sell	20,355	$73.24	$1,490,800.20	47,101
8/13/2020	Sell	2,249	$78.24	$175,961.76	26,746
7/14/2020	Sell	2,249	$67.66	$152,167.34	28,995
6/16/2020	Sell	3,348	$70.67	$236,603.16
6/11/2020	Sell	2,249	$68.06	$153,066.94	34,564
5/13/2020	Sell	750	$216.93	$162,697.50	18,318
4/16/2020	Sell	1,116	$216.91	$242,071.56	14,755
3/23/2020	Sell	1,116	$162.95	$181,852.20	15,773
2/18/2020	Sell	2,500	$228.57	$571,425.00	19,389
12/16/2019	Sell	2,500	$234.27	$585,675.00	19,605
11/15/2019	Sell	2,500	$242.14	$605,350.00	19,605
10/25/2019	Sell	2,500	$227.19	$567,975.00	19,605
9/19/2019	Sell	2,500	$216.71	$541,775.00	20,138
8/15/2019	Sell	372	$214.53	$79,805.16	18,010
7/15/2019	Sell	1,152	$191.70	$220,838.40	19,162
6/14/2019	Sell	1,474	$184.55	$272,026.70	20,250
5/15/2019	Sell	1,474	$177.92	$262,254.08	21,396
4/15/2019	Sell	1,474	$192.00	$283,008.00	21,132
3/15/2019	Sell	1,146	$179.10	$205,248.60	22,229
2/21/2019	Sell	1,474	$176.34	$259,925.16	15,905
1/15/2019	Sell	700	$155.00	$108,500.00	24,482
10/15/2018	Sell	700	$142.64	$99,848.00	27,772
5/24/2018	Sell	9,815	$139.39	$1,368,112.85	20,012
7/31/2017	Sell	4,681	$115.78	$541,966.18
11/30/2016	Buy	12,870	$83.43	$1,073,744.10

See Full Table

Catherine M. Szyman Buying and Selling Activity at Edwards Lifesciences

Edwards Lifesciences Company Overview

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Today's Range

Now: $70.90

$70.63

$71.66

50 Day Range

MA: $71.49

$67.92

$76.23

2 Week Range

Now: $70.90

$58.93

$95.73

Volume

4,513,774 shs

Average Volume

4,808,659 shs

Market Capitalization

$41.68 billion

P/E Ratio

10.17

Dividend Yield

N/A

Beta

1.12